The Effect of Betahistine on Body Weight and Waist Circumference in Obese Adults in Comparison with Orlistat
Abstract
Obesity is a chronic disease in which excess body fat has accumulated and it may affect the health. People who are overweight or obese, compared to those with a healthy weight, are at increased risk for many serious diseases. Two classes of drugs are used in treating obesity: anorexiants and lipase inhibitors. Phentermine and Amfepramone (anorexiants) are indicated for short-term treatment of obesity while orlistat (lipase inhibitors) is approved for long-term treatment, up to 4 years of use.Aim of the Study: The study was designed to assess the effect of betahistine in lowering the body weight and/or decreasing waist circumference. Patients and Methods: The study sample included 60 patients with established overweight or obesity and were divided randomly into 2 groups, 30 patients per group and the body weight and waist circumference were measured every 10 days for 30 days. Each patient was informed about the treatment.Results: In betahistine treatment group, there was a highly significant reduction in body weight and waist circumference after 10, 20 and 30 days compared to baseline levels (P< 0.01). In multiple comparisons among orlistat and betahistine groups, there was no significant difference (P > 0.05) in body weight and waist circumference after 10, 20 and 30 days of treatment.Conclusions: Each of orlistat and betahistine exert a reduction effect on body weight and waist circumference. The present study reveals that there are no significant differences between orlistat and betahistine in reducing the body weight and waist circumference
Metrics